The US regulator says Retevmo (selpercatinib, formerly LOXO-292) can be used to treat lung and thyroid cancers with a mutation or fusion in the RET gene, specifically non-small cell lung cancer ...

NTRK fusion cancer is rare, affecting no more than a ... and is more common in sarcomas, brain, kidney and thyroid cancers. Use of the drug will depend on patients receiving genetic testing ...

NTRK fusion genes occur in various types of adult and pediatric tumors. In some rare tumors, such as salivary gland carcinoma, secretory breast cancer, and infantile fibrosarcoma, the incidence of ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

British Journal of Cancer, part of leading science journal Nature, published a paper entitled "Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK ...

for advanced solid tumours harbouring neurotrophic tyrosine receptor kinase (NTRK) fusion genes. Previously, the CDE had accepted the new drug application (NDA) for the pan-tropomyosin receptor ...

Lower Screening Age Calls for More Tailored Bowel Cancer Surveillance Apr. 30, 2025 — Australia's recent move to lower the starting age for bowel (colorectal) cancer screening from 50 down to 45 ...

Whether you need to boost team morale or just want to give your friends a good laugh, lead with your funny bone, Cancer. With unpredictable Uranus getting in on the action, the element of surprise ...